CryoLife
This article was originally published in The Gray Sheet
Executive Summary
Board authorizes repurchase of up to 1 mil. shares of common stock. Separately, the Atlanta-based maker of human tissue implantable devices reported a 10% increase in third quarter revenues to $16 mil. Net income, excluding effects of the sale of the firm's Ideas for Medicine business, was up 31% to $1.9 mil. Including the sale, net income was up 118.7% to $3.2 mil
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.